期刊
ONCOTARGET
卷 6, 期 13, 页码 11139-11149出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.3576
关键词
PD-L1; TILs; chordoma; immunotherapy
资金
- Stephan L. Harris Fund
- Gattegno and Wechsler funds
- Jennifer Hunter Yates Foundation
- Chordoma Foundation
- Sarcoma Foundation of America (SFA)
- National Cancer Institute (NCI)/National Institutes of Health (NIH), UO1 [CA151452-01]
- Sarcoma SPORE/NIH
- Academic Enrichment Fund of MGH Orthopedic Surgery
- National Natural Science Foundation of China (NSFC) [81101375]
Chordomas are primary malignant tumors of the notochord that are resistant to conventional chemotherapy. Expression of programmed cell death ligand 1 (PD-L1), prevalence of tumor-infiltrating lymphocytes (TILs), and their clinical relevance in chordoma remain unknown. We evaluated PD-L1 expression in three chordoma cell lines and nine chordoma tissue samples by western blot. Immunohistochemical staining was performed on a chordoma tissue microarray (TMA) that contained 78 tissue specimens. We also correlated the expression of PD-L1 and TILs with clinical outcomes. PD-L1 protein expression was demonstrated to be induced by IFN-. in both UCH1 and UCH2 cell lines. Across nine human chordoma tissue samples, PD-L1 protein was differentially expressed. 94.9% of chordoma samples showed positive PD-L1 expression in the TMA. The expression score of PD-L1 for metastatic chordoma tumors was significant higher as compared with non-metastatic chordoma tumors. Expression of PD-L1 protein significantly correlates with the presence of elevated TILs, which correlates with metastasis. In summary, our study showed high levels of PD-L1 are expressed in chordoma, which is correlated with the prevalence of TILs. The current study suggests targeting PD-L1 may be a novel immunotherapeutic strategy for chordoma clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据